NEW YORK, Feb. 10, 2006 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company, including the KRX-101 (sulodexide) Phase II data and the ongoing Phase III/IV clinical program, at The BIO CEO and Investor Conference in New York City. Mr. Weiss' presentation will take place on Wednesday, February 15, 2006 at 12:00 noon Eastern Time in the Astor Salon of the Waldorf = Astoria Hotel. A live audio webcast of Mr. Weiss' presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=KERX&item_id=1165945. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life- threatening kidney disease caused by diabetes. KRX-101 is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.